Literature DB >> 11285130

Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology.

H J Noreen1, N Yu, M Setterholm, M Ohashi, J Baisch, R Endres, M Fernandez-Vina, U Heine, S Hsu, M Kamoun, Y Mitsuishi, D Monos, L Perlee, S Rodriguez-Marino, A Smith, S Y Yang, K Shipp, J Hegland, C K Hurley.   

Abstract

A total of 42,160 individuals were typed for HLA-A and HLA-B by both serology and PCR-based typing. The HLA assignments included all of the known serological equivalents. The majority of the individuals (99.9%) were from U.S. minority population groups. The serologic typing was performed between 1993 and 1997 at the time of recruitment for the National Bone Marrow Program (NMDP) registry. The polymerase chain reaction (PCR)-based typing was carried out in two phases. In phase I, DNA typing was performed by PCR using sequence-specific oligonucleotide probes (PCR-SSOP) or PCR using sequence-specific primers (PCR-SSP) without knowledge of the serologic assignments. Discrepancies were identified between the serologic and DNA assignments in 24% of the volunteers (8% of volunteers differed for only HLA-A assignments, 13% for HLA-B, and 3% for both HLA-A and -B) and a potential explanation was assigned each discrepant serology/DNA pair. In phase II, a random sampling scheme was used to select a statistically significant number of individuals for repeat DNA typing from each of these categories. The categories included antigens missed by serology, nonexpressed (null) alleles, PCR amplification failures, misassignment of antigens and nomenclature issues. Only a single individual was found to carry a null allele. DNA-based testing correctly typed nearly 99% of the donors at HLA-A, more than 98% at HLA-B, and more than 97% at both HLA-A and -B validating this methodology for registry typing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285130     DOI: 10.1034/j.1399-0039.2001.057003221.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

1.  Donor registries and search strategies.

Authors:  Carolyn K Hurley; Machteld Oudshoorn; Michelle Setterholm
Journal:  Methods Mol Biol       Date:  2012

2.  Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Authors:  Claudio G Brunstein; Effie W Petersdorf; Todd E DeFor; Harriet Noreen; David Maurer; Margaret L MacMillan; Celalettin Ustun; Michael R Verneris; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-30       Impact factor: 5.742

Review 3.  HLA diversity: detection and impact on unrelated hematopoietic stem cell donor characterization and selection.

Authors:  Carolyn Katovich Hurley
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Authors:  Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

5.  Rapid assignment of swine leukocyte antigen haplotypes in pedigreed herds using a polymerase chain reaction-based assay.

Authors:  Gregory W Martens; Joan K Lunney; Judy E Baker; Douglas M Smith
Journal:  Immunogenetics       Date:  2003-08-21       Impact factor: 2.846

6.  Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research.

Authors:  M R Bishop; B R Logan; S Gandham; B J Bolwell; J-Y Cahn; H M Lazarus; M R Litzow; D I Marks; P H Wiernik; P L McCarthy; J A Russell; C B Miller; J Sierra; G Milone; A Keating; F R Loberiza; S Giralt; M M Horowitz; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2007-12-17       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.